Key statistics
On Saturday, Biohaven Ltd (BHVN:NYQ) closed at 41.43, 54.59% above the 52 week low of 26.80 set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.17 |
---|---|
High | 42.82 |
Low | 41.22 |
Bid | 40.44 |
Offer | 42.70 |
Previous close | 41.79 |
Average volume | 823.34k |
---|---|
Shares outstanding | 101.12m |
Free float | 85.42m |
P/E (TTM) | -- |
Market cap | 3.89bn USD |
EPS (TTM) | -9.35 USD |
Data delayed at least 15 minutes, as of Feb 15 2025.
More ▼
- Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
- Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
- Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
- Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
- Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
More ▼